Levo floxacin (Quinsair®) for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa
The National Health Care Institute carried out a marginal assessment of the medicine levofloxacin (Quinsair®), whereby they came to the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), levofloxacin can be regarded as mutually replaceable with three other drugs for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa , so it can be included in the GVS on List 1A in cluster 0J01GBAII V with a standard dose of 240 mg.